TuppenHAFehmiJCzerminBGoffriniPMeloniFFerreroIet al
Adding multi-day fasting to pharmacological appetite suppression creates risk of hypoglycemia, severe electrolyte imbalance, excessive muscle breakdown, nutrient deficiency, and in people with type 2 diabetes, dangerous metabolic instability
NICE guidance recommends its use within specialist weight management services for eligible patients who meet specific BMI criteria (generally 35 kg/m with weight-related comorbidity, or 30 kg/m with type 2 diabetes) for a maximum treatment duration of two years
Choosing a GLP-1 provider involves more than platform convenienceit requires understanding clinical eligibility, medication options, ongoing support, and whether precision diagnostics might enhance treatment personalization
These effects were typically most pronounced during the dose escalation period and tended to diminish over time as the body adjusted to the medication
R., & Ballmann, C